Telix Pharmaceuticals company profile

TLX · ASX · AUD

Compare Telix Pharmaceuticals
$12.92Change from previous close: −2.27%Absolute change: −$0.30

Close · November 20, 2026

Company profile

Telix Pharmaceuticals has 1,120 employees and is headquartered in North Melbourne, Australia.

Telix Pharmaceuticals develops and commercializes radiopharmaceuticals, both therapeutic and diagnostic, and its largest segment is Precision Medicine, built around imaging agents such as Illuccix and Gozellix for prostate cancer. Its pipeline includes the lutetium-labeled radio antibody-drug conjugate TLX591, which is in a Phase 3 trial for advanced prostate cancer, along with candidates for kidney cancer, glioblastoma, soft tissue sarcoma and bone metastases. The company also operates a Therapeutics segment and a Manufacturing Solutions segment, and it serves customers in Australia, Belgium, Canada, the United Kingdom, the United States and other markets, with a strategic collaboration with University Hospital Essen.

Revenue reached USD 803.8 million in the fiscal year ended December 2025, up 55.6% from the previous year, while the company posted a net loss of USD 7.1 million for the same period. Telix had 1,120 employees and is headquartered in North Melbourne, Australia. The company was founded in 2015.

Company facts

Industry
Biotechnology
Country
Australia
Headquarters
55 Flemington Road, 3051, North Melbourne
Employees
1,120
Chief executive
Christian Behrenbruch
Founded
2015
Fiscal year
January - December
Listing
TLX · ASX
Currency
AUD
ISIN
AU000000TLX2

Telix Pharmaceuticals and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Telix PharmaceuticalsTLXAustralia$2.92B1,1206.2%92.3
InSilico Medicine Cayman TopCo3696Hong Kong SAR China$2.59B333-6.9%—
3SBio1530Hong Kong SAR China$4.56B6,06860.3%3.90
Neuren PharmaceuticalsNEUAustralia$1.83B819.9%144.0
MesoblastMSBAustralia$1.48B108-42.6%—
Akeso9926Hong Kong SAR China$6.81B4,082-30.7%—

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Telix Pharmaceuticals with its competitors